Scientists discover a surprising link between vitamin C and cancer survival
A clinical trial suggests that daily vitamin C supplementation may improve survival outcomes for patients with precancerous blood disorders and early-stage blood cancers. While the supplement did not stop the progression of abnormal cells, it was linked to lower inflammation and higher survival rates.
Why it matters
This finding could lead to a low-cost, accessible supportive therapy for patients battling blood-related malignancies.
Vitamin C plays an important role in keeping the immune system healthy, helping wounds heal, and protecting cells from damage. However, people with precancerous blood disorders and blood cancers often have persistently low vitamin C levels. Researchers have been investigating whether correcting this deficiency could improve their health and treatment outcomes.
New findings from the phase 2 EVITA clinical trial suggest that vitamin C supplementation may offer important benefits for people with precancerous blood conditions and early-stage blood cancers. The randomized, double-blind, placebo-controlled study was conducted by the Van Andel Institute-Stand Up To Cancer(r) Epigenetics Dream Team.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in